psalexa
logo

Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2018

Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: February 2018
Report Code: LS11041
Available Format:
Pages: 151

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Classification of AKI

4.1.1.1 General classification

4.1.1.2 Classification based on daily urine excretion

4.1.1.3 RIFLE classification system for AKI

4.1.1.4 AKI network classification system

4.2 Causes and Risk Factors

4.2.1 Causes of AKI

4.2.1.1 Reduced blood flow to kidneys

4.2.1.2 Damage to kidneys

4.2.1.3 Obstruction to the drainage of kidneys

4.2.2 Risk Factors of AKI

4.3 Symptoms

4.3.1 Complications

4.4 Diagnosis

4.5 Treatment

4.5.1 Treatment of the Underlying Cause of AKI

4.5.2 Treatment of Symptoms/Complications Associated with AKI

4.6 Prevention

4.7 Epidemiology

4.8 Key Drivers

4.8.1 Research Funding from Various Agencies

4.8.2 No Approved Treatment

4.9 Key Barriers

4.9.1 Discontinuation of Drugs

4.10 Acute Kidney Injury Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. Acute Kidney Injury Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 RESCAP

5.1.1.1 Clinical trials

5.1.1.2 Grant

5.1.1.3 Patents

5.1.2 XXXX

5.1.2.1 Clinical trials

5.2 Phase II/III

5.2.1 Levosimendan

5.2.1.1 Clinical trials

5.2.2 XXXX

5.2.2.1 Clinical trials

5.3 Phase II

5.3.1 Elamipretide

5.3.1.1 Collaboration

5.3.1.2 Technology

5.3.2 XXXX

5.3.2.1 Clinical trials

5.3.3 XXXX

5.3.3.1 Pre-Clinical results

5.3.3.2 Clinical trials

5.3.4 XXXX

5.3.4.1 Clinical trials

5.3.4.2 Funding

5.3.5 XXXX

5.3.5.1 Pre-Clinical results

5.3.5.2 Clinical trials

5.3.5.3 Technology

5.3.6 XXXX

5.3.6.1 Clinical trials

5.3.6.2 Clinical trial results

5.3.6.3 Pre-Clinical results

5.3.6.4 Funding

5.3.6.5 Strategic developments

5.3.7 XXXX

5.3.7.1 Clinical trials

5.3.7.2 Clinical trial results

5.3.7.3 Strategic developments

5.3.8 XXXX

5.3.8.1 Clinical trials

5.4 Phase I/II

5.4.1 SBI-101

5.4.1.1 Clinical trials

5.4.1.2 Grants

5.5 Phase I

5.5.1 XXXX

5.5.1.1 Clinical trials

5.5.1.2 Clinical trial results

5.5.1.3 Technology

5.5.2 XXXX

5.5.3 XXXX

5.5.3.1 Clinical trials

5.5.4 XXXX

5.5.4.1 Pre-Clinical result

5.5.4.2 Clinical trials

5.5.4.3 Strategic developments

5.6 IND

5.6.1 XXXX

5.6.1.1 Pre-Clinical results

5.6.1.2 Patent

5.6.1.3 Technology

5.6.1.4 Strategic developments

5.7 Pre-Clinical

5.7.1 XXXX

5.7.1.1 Pre-Clinical results

5.7.1.2 Clinical trials

5.7.1.3 Collaboration

5.7.1.4 Patent

5.7.2 XXXX

5.7.2.1 Technology

5.7.3 XXXX

5.7.3.1 Technology

5.7.4 XXXX

5.7.4.1 Strategic developments

5.7.5 XXXX

5.7.5.1 Pre-Clinical results

5.7.6 XXXX

5.7.6.1 Strategic developments

5.7.7 XXXX

5.7.7.1 Pre- Clinical study

5.7.8 XXXX

5.7.8.1 Pre-Clinical trials

5.7.8.2 Patents

5.7.8.3 Other

5.7.9 XXXX

5.7.9.1 Pre-Clinical Result

5.7.10 XXXX

5.7.10.1 Patents

5.7.10.2 Technology

5.7.10.3 Strategic developments

5.7.11 XXXX

5.7.11.1 Pre-Clinical results

5.7.11.2 Strategic developments

5.7.12 XXXX

5.7.12.1 Pre-Clinical study

5.7.13 XXXX

5.7.13.1 Pre-Clinical result

5.7.14 XXXX

5.7.14.1 Pre-Clinical results

5.7.14.2 Technology

5.7.15 XXXX

5.7.16 XXXX

5.7.16.1 Pre-Clinical results

5.7.17 XXXX

5.7.17.1 Pre-Clinical results

5.7.18 XXXX

5.7.18.1 Pre-Clinical result

5.8 Discovery

5.8.1 XXXX

5.8.2 XXXX

5.8.2.1 Strategic developments

5.8.3 XXXX

5.8.3.1 Patents

5.9 Unknown

5.9.1 XXXX

5.9.1.1 Strategic developments

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for AKI Therapeutics Pipeline

7.2 SWOT Analysis of AKI Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Angion Biomedica Corp.

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 Company 2

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product & Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product & Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product & Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product & Service Offerings

8.1 Company 10

8.10.1 Business Overview

8.10.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 GENERAL CLASSIFICATION OF AKI

TABLE 2 CLASSIFICATION OF AKI BASED ON DAILY URINE EXCRETION

TABLE 3 STAGES OF AKI UNDER RIFLE CLASSIFICATION SYSTEM

TABLE 4 STAGES OF AKI UNDER AKIN CLASSIFICATION SYSTEM

TABLE 5 PIPELINE ANALYSIS OF AKI THERAPEUTICS, BY COMPANY (2018)

TABLE 6 DESCRIPTION OF RESCAP

TABLE 7 CLINICAL TRIALS OF RESCAP

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF LEVOSIMENDAN

TABLE 11 CLINICAL TRIALS OF LEVOSIMENDAN

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 DESCRIPTION OF ELAMIPRETIDE

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIALS OF XXXX

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 CLINICAL TRIALS OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 CLINICAL TRIALS OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 CLINICAL TRIALS OF XXXX

TABLE 29 DESCRIPTION OF SBI- 101

TABLE 30 CLINICAL TRIALS OF SBI-101

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 CLINICAL TRIALS OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 CLINICAL TRIALS OF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 DESCRIPTION OF XXXX

TABLE 40 DESCRIPTION OF XXXX

TABLE 41 DESCRIPTION OF XXXX

TABLE 42 DESCRIPTION OF XXXX

TABLE 43 DESCRIPTION OF XXXX

TABLE 44 DESCRIPTION OF XXXX

TABLE 45 DESCRIPTION OF XXXX

TABLE 46 DESCRIPTION OF XXXX

TABLE 47 DESCRIPTION OF XXXX

TABLE 48 DESCRIPTION OF XXXX

TABLE 49 DESCRIPTION OF XXXX

TABLE 50 DESCRIPTION OF XXXX

TABLE 51 DESCRIPTION OF XXXX

TABLE 52 DESCRIPTION OF XXXX

TABLE 53 DESCRIPTION OF XXXX

TABLE 54 DESCRIPTION OF XXXX

TABLE 55 DESCRIPTION OF XXXX

TABLE 56 DESCRIPTION OF XXXX

TABLE 57 DESCRIPTION OF XXXX

TABLE 58 DESCRIPTION OF XXXX

TABLE 59 DESCRIPTION OF XXXX

TABLE 60 ANGION BIOMEDICA CORP. – AT A GLANCE

TABLE 61 COMPANY 2 - AT A GLANCE

TABLE 62 COMPANY 3 - AT A GLANCE

TABLE 63 COMPANY 4 - AT A GLANCE

TABLE 64 COMPANY 5 - AT A GLANCE

TABLE 65 COMPANY 6 - AT A GLANCE

TABLE 66 COMPANY 7 - AT A GLANCE

TABLE 67 COMPANY 8 - AT A GLANCE

TABLE 68 COMPANY 9 - AT A GLANCE

TABLE 69 COMPANY 10 - AT A GLANCE

 

LIST OF FIGURES

 

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: GENERAL CLASSIICATION OF AKI

FIG 5: CLINICAL DIAGNOSIS OF AKI

FIG 6: TREATMENT ALGORITHM FOR AKI

FIG 7: AKI DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 8: AKI PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 9: AKI PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 10: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12: KEY PLAYERS BENCHMARKING

FIG 13: SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry